ATTAIN and ACHIEVE are the key phase 3 programmes behind orforglipron and the U.S. Foundayo approval story. They matter because they show that oral GLP-1 treatment is moving beyond semaglutide alone. They do not, by themselves, answer whether the medicine is licensed or available in the UK.
ATTAIN and ACHIEVE are important because they make oral GLP-1 treatment look like a durable research direction rather than a one-product curiosity. ATTAIN is the obesity side of that story. ACHIEVE is the diabetes side. Together, they help explain why Foundayo became such a large U.S. development in 2026.
ATTAIN asks whether oral orforglipron can deliver meaningful weight-loss results in adults with obesity who do not have diabetes. That makes it one of the most relevant study families for readers following the future of oral obesity treatment.
ACHIEVE asks whether oral orforglipron works in people with type 2 diabetes. That matters because it shows the molecule has a broader metabolic role and is not simply a single-use weight-loss headline.
| Evidence item | Population and design | Main signal | UK meaning |
|---|---|---|---|
| ATTAIN-1 | Adults with obesity and without diabetes; multinational, randomised, double-blind phase 3 trial. | Mean body-weight change at week 72 was reported as -7.5%, -8.4% and -11.2% with tested doses versus -2.1% with placebo. | Shows that oral orforglipron can produce clinically meaningful weight-loss results. It does not create a current UK route. |
| ACHIEVE-1 | People with early type 2 diabetes; phase 3 oral orforglipron evidence. | Public summaries report HbA1c reductions of about 1.3 to 1.6 percentage points. | Shows the molecule has broader diabetes relevance and should not be described only as an obesity-market story. |
| FDA Foundayo approval | U.S. regulatory approval announcement dated 1 April 2026. | Confirms that the U.S. moved from trial evidence to approval. | Important category news, but not proof of UK licensing, NHS access, or a UK prescribing pathway. |
These studies support the statement that oral GLP-1 treatment is expanding fast in the U.S. They do not support shortcuts such as "the UK has Foundayo now" or "Foundayo replaces Rybelsus as the current UK oral answer."